DDInter820 DDInter1376
Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Ginseng {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Ginseng {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Ginseng {u} may lead to a major life threatening interaction when taken with {v} Imatinib
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Ginseng may lead to a major life threatening interaction when taken with Imatinib